B of A Securities Upgrades 10x Genomics to Neutral, Raises Price Target to $54
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Derik De Bruin upgraded 10x Genomics (NASDAQ:TXG) from Underperform to Neutral and increased the price target from $36 to $54.

December 12, 2023 | 12:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
10x Genomics was upgraded by B of A Securities from Underperform to Neutral, with a price target increase from $36 to $54, indicating a more favorable outlook on the stock.
Upgrades by analysts, especially from Underperform to Neutral, typically signal a positive change in the stock's outlook, which can lead to increased investor confidence and potential short-term price appreciation. The substantial raise in the price target further supports a bullish sentiment.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100